1-8 of 8
Michael Leukam
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 2 Study of Epcoritamab in Patients with Follicular Lymphoma Not Achieveing a Complete Response with Front-Line Chemoimmunotherapy (EPCON)

Gottfried von Keudell, Emma K Logan, Robert A. Redd, Michael Leukam, Matthew Weinstock, Jon E. Arnason, Ranjana H. Advani
Journal: Blood
Blood (2024) 144 (Supplement 1): 6284.
https://doi.org/10.1182/blood-2024-206520
Published: 2024
Journal Articles

Infectious Complications in B-Cell Non-Hodgkin Lymphoma (NHL) Patients Treated with Bispecific Antibody Therapy (BsAb) As Compared to Chimeric Antigen Receptor T-Cell Therapy (CAR-T)

Genevieve M Gerhard, Robert A. Redd, Poorva Bindal, Carolyn D Alonso, Rushad Patell, Michael Leukam, Jon E. Arnason, Matthew Weinstock, Gottfried von Keudell
Journal: Blood
Blood (2024) 144 (Supplement 1): 6554.
https://doi.org/10.1182/blood-2024-199156
Published: 2024
Journal Articles

ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy

Jason R. Westin, Alex F. Herrera, Ryan Lynch, Jeremy S. Abramson, Don A. Stevens, Matthew Matasar, Lindsey Fitzgerald, Alan P Skarbnik, Chaitanya Iragavarapu, James H Essell, Bradley D. Hunter, Akil Merchant, Indumathy Varadarajan, Anand Tandra, Edward Licitra, Locke Johnson Bryan, Rushang D. Patel, Rajesh Behl, Jeff P. Sharman, Houston Holmes, Habte A. Yimer, Mitul Gandhi, Nosha Farhadfar, Nancy L. Bartlett, Michael Leukam, Tahir Latif, Paolo Caimi, Jean Yared, Amy Feng, Lynn Navale, Sri Ghatta, John B. Le Gall, Zachary J Roberts, John M. Burke
Journal: Blood
Blood (2024) 144 (Supplement 1): 3132.1.
https://doi.org/10.1182/blood-2024-194909
Published: 2024
Journal Articles

Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)

Austin I. Kim, Philippe Armand, Christine E. Ryan, Robert A. Redd, Megan Forsyth, Juniper Mai, Samantha Pazienza, Caitlin Bresnahan, Vanessa M Kats, Salah Abdulkarim, Susan M Waisgerber, Reid W. Merryman, David C. Fisher, Inhye E. Ahn, Jennifer L. Crombie, Oreofe O. Odejide, Ann S. LaCasce, Caron A. Jacobson, Eric D. Jacobsen, Erin M. Parry, David A. Qualls, Amy C. Bessnow, Matthew S. Davids, Jennifer R. Brown, Jon E. Arnason, Michael Leukam, Peter A. Riedell, Mark A. Murakami
Journal: Blood
Blood (2024) 144 (Supplement 1): 4408.
https://doi.org/10.1182/blood-2024-198056
Published: 2024
Journal Articles

G-CSF Administration Is Associated with Worse Treatment Response and Survival after CAR T-Cell Therapy

Poorva Bindal, Pavania Elavalakanar, Caitlin A. Trottier, Laura E. Dodge, Emma K. Logan, David J. Sermer, Michael Leukam, Matthew J Weinstock, Robin M. Joyce, Jessica Liegel, Jacalyn Rosenblatt, David Avigan, Carolyn D. Alonso, Jon E. Arnason
Journal: Blood
Blood (2022) 140 (Supplement 1): 5238–5240.
https://doi.org/10.1182/blood-2022-167976
Published: 2022
Journal Articles

A Multicenter, Single-Arm, Phase I/II Dose Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Minimally-Pretreated Follicular Lymphoma

Kirk Cahill, Michael Leukam, Theodore G. Karrison, Jessica Robertson, Justin Kline, Sonali M. Smith
Journal: Blood
Blood (2021) 138 (Supplement 1): 2420.
https://doi.org/10.1182/blood-2021-152126
Published: 2021
Journal Articles

Integrative Immunogenomic Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Identifies Four Molecular Subtypes with Distinct Immune Landscapes

Michael Leukam, MDMS, James Godfrey, MD, Sravya Tumuluru, Girish Venkataraman, MD MBBS, Sonali M. Smith, MD, Riyue Bao, PhD, Justin Kline, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 924.
https://doi.org/10.1182/blood-2019-131562
Published: 2019
Journal Articles

PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell–inflamed phenotype

James Godfrey, Sravya Tumuluru, Riyue Bao, Michael Leukam, Girish Venkataraman, John Phillip, Carrie Fitzpatrick, James McElherne, Brendan W. MacNabb, Robert Orlowski, Sonali M. Smith, Justin Kline
Journal: Blood
Blood (2019) 133 (21): 2279–2290.
https://doi.org/10.1182/blood-2018-10-879015
Published: 2019
Includes: Supplemental data